Literature DB >> 6201971

Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.

M Kirmani, M Santana, N Sorgente, P Wiedemann, S J Ryan.   

Abstract

We used an experimental model of proliferative vitreoretinopathy (PVR) and cell-induced traction retinal detachment to study the therapeutic value of six cytotoxic drugs (actinomycin C, colchicine, cytosine arabinoside hydrochloride, 5-fluorodeoxyuridine, vinblastine sulfate, and daunomycin). Pigmented rabbits were injected with 2.5 X 10(5) cultured homologous dermal fibroblasts. At the same time, cytotoxic drugs were injected into the vitreous in an attempt to inhibit cellular proliferation. The sensitivity of the cells to the drug was also tested in vitro before injection. Daunomycin at a dose of 10 nmol per eye stopped cellular proliferation and subsequent traction retinal detachment in vivo. The electroretinogram (ERG) showed no evidence of drug-induced retinal toxicity with this dose of daunomycin. No alteration in frequency or severity of vitreal membranes and retinal detachment was observed after injection of equivalent doses of the other drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6201971     DOI: 10.1097/00006982-198300340-00007

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  9 in total

1.  Evaluation of radiation therapy for experimental proliferative vitreoretinopathy in rabbits.

Authors:  S Kuriyama; T Ohuchi; N Yoshimura; Y Honda; M Hiraoka; M Abe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro.

Authors:  J Cai; R Wei; X Ma; H Zhu; Y Li
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

3.  Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro.

Authors:  M Weller; K Heimann; P Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1987       Impact factor: 3.117

4.  Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study.

Authors:  C H Kon; R H Asaria; N L Occleston; P T Khaw; G W Aylward
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

Review 5.  Proliferative vitreoretinopathy--is it anything more than wound healing at the wrong place?

Authors:  M Weller; P Wiedemann; K Heimann
Journal:  Int Ophthalmol       Date:  1990-03       Impact factor: 2.031

6.  Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells.

Authors:  Jia-Qi Yao; Qing-Huai Liu; Xi Chen; Qin Yang; Zhi-Yang Xu; Fan Hu; Lin Wang; Jian-Min Li
Journal:  J Biomed Sci       Date:  2010-04-23       Impact factor: 8.410

7.  Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy.

Authors:  J A Khawly; P Saloupis; D L Hatchell; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

8.  Taxol treatment of experimental proliferative vitreoretinopathy.

Authors:  S A Daniels; K G Coonley; M O Yoshizumi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

9.  Inhibitory Effects of Plumbagin on Retinal Pigment Epithelial Cell Epithelial-Mesenchymal Transition In Vitro and In Vivo.

Authors:  Haiting Chen; Huifang Wang; Jianbin An; Qingli Shang; Jingxue Ma
Journal:  Med Sci Monit       Date:  2018-03-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.